Pfizer said total revenues for Q2 2025 were $14.7 billion, an increase of $1.4 billion, or 10%, from $13.3 billion in the prior-year period. The impact of foreign exchange was de minimis, and the operational increase was $1.3 billion, or 10%.

10-QQuarterly reportFiled Aug 5, 2025Period of report Jun 29, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

Pfizer said total revenues for Q2 2025 were $14.7 billion, an increase of $1.4 billion, or 10%, from $13.3 billion in the prior-year period. The impact of foreign exchange was de minimis, and the operational increase was $1.3 billion, or 10%.
The company said total revenues for the first six months of 2025 were $28.4 billion, an increase of $205 million, or 1%, from $28.2 billion in the prior-year period. The operational increase was $439 million, or 2%, partially offset by an unfavorable impact of foreign exchange of $234 million, or 1%.
Pfizer said income from continuing operations before provision for taxes on income for Q2 was $3.0 billion, compared to a loss of $103 million in the prior-year period. The company cited higher revenues, a decrease in restructuring charges and certain acquisition-related costs, and net gains on equity securities versus net losses on equity securities in the prior-year period as factors, partially offset by an increase in cost of sales.
Pfizer completed an exclusive global, ex-China, in-licensing agreement with 3SBio for SSGJ-707 in July 2025, the company said. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments of up to $4.8 billion. The company said it will record a charge of $1.35 billion in Q3 in Acquired in-process research and development expenses.

Key figures

Quarter ended June 29, 2025

Revenue: $14.7B
Net income: $2.9B
EPS: $0.51

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q2 Total Revenues $14.7 billion, Up 10%

Pfizer said total revenues for Q2 2025 were $14.7 billion, an increase of $1.4 billion, or 10%, from $13.3 billion in the prior-year period. The impact of foreign exchange was de minimis, and the operational increase was $1.3 billion, or 10%.

Source · Based on the MD&A text of the filing

First-Half Total Revenues $28.4 billion and Foreign Exchange Impact

The company said total revenues for the first six months of 2025 were $28.4 billion, an increase of $205 million, or 1%, from $28.2 billion in the prior-year period. The operational increase was $439 million, or 2%, partially offset by an unfavorable impact of foreign exchange of $234 million, or 1%.

Source · Based on the MD&A text of the filing

Q2 income before taxes $3.0 billion vs. prior-year loss $103 million

Pfizer said income from continuing operations before provision for taxes on income for Q2 was $3.0 billion, compared to a loss of $103 million in the prior-year period. The company cited higher revenues, a decrease in restructuring charges and certain acquisition-related costs, and net gains on equity securities versus net losses on equity securities in the prior-year period as factors, partially offset by an increase in cost of sales.

Source · Based on the MD&A text of the filing

3SBio and SSGJ-707 License: Upfront Payment $1.25 billion

Pfizer completed an exclusive global, ex-China, in-licensing agreement with 3SBio for SSGJ-707 in July 2025, the company said. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments of up to $4.8 billion. The company said it will record a charge of $1.35 billion in Q3 in Acquired in-process research and development expenses.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.